The Food and Drug Administration (FDA) awarded a firm fixed-price purchase order to Carterra Inc., a Salt Lake City-based manufacturer of surface plasmon resonance (SPR) scientific instrumentation, for unlimited emergency repair services on an Ascent-level Carterra Label-Free Screening Array (LSA) instrument. The contract, designated as a total small business set-aside, was awarded on July 18, 2024, with a ceiling value of $23,587.47 and an ultimate completion date of April 16, 2025. The solicitation, posted on May 3, 2024, sought comprehensive maintenance and repair services including all labor, travel, original equipment manufacturer (OEM) replacement parts, technical support, and preventative maintenance for the SPR equipment located at the FDA's Center for Biologics Evaluation and Research (CBER) in Silver Spring, Maryland. The contract was structured with a base year plus three option years, though the award notice reflects abbreviated performance dates, potentially indicating a termination for convenience settlement agreement referenced in the contract description related to the Department of Government Efficiency cost efficiency initiative.
Carterra Inc. has maintained an established relationship with the FDA and other Department of Health and Human Services agencies, having previously secured multiple contracts for supplying and servicing LSA instruments in support of biomedical research initiatives, including COVID-19 research efforts. The company, registered in the System for Award Management (SAM.gov) since November 2005, specializes in providing sophisticated laboratory equipment and related services for molecular interaction analysis critical to infectious disease research, antibody production, and vaccine development. This contract award reflects the FDA's continued reliance on Carterra as the specialized vendor for maintaining and supporting its SPR instrumentation infrastructure.
Generated 12/28/25, 1:35 AM